MAG
NAGE

Millrace Asset Group’s Niagen Bioscience NAGE Stock Holding History

Millrace Asset Group’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$93K Buy
+25,503
New +$80.3K 0.09% 70

Other funds holding NAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Millrace Asset Group's NAGE Position: Q3 2024 in Review

Millrace Asset Group opened a new position in Niagen Bioscience (NAGE) in Q3 2024: 25,503 shares worth $93K. The stake represents 0.09% of the portfolio and ranks #70 among its holdings.

91 funds tracked by Wall St. Rank hold NAGE as of Q3 2024.

  • Millrace Asset Group held 25,503 shares of Niagen Bioscience worth $93K as of Q3 2024.
  • Niagen Bioscience was a new Millrace Asset Group position in Q3 2024.
  • Niagen Bioscience made up 0.09% of Millrace Asset Group's portfolio in Q3 2024, its #70 holding.
  • 91 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2024.

Based on Millrace Asset Group's 13F filing for Q3 2024, filed 13 Nov 2024.